Therapeutic Target Discovery Platform
Neurodegenerative Diseases
DiscoveryActive
Key Facts
About ValtedSeq
ValtedSeq is a private, pre-clinical biotech company pioneering a data-driven approach to neurodegenerative diseases. Founded by renowned Johns Hopkins scientists Dr. Ted Dawson and Dr. Valina Dawson, the company's core asset is its HiF-Seq™ platform, which enables high-efficiency single-cell sequencing from frozen brain tissue to create an unprecedented data repository. This data fuels the discovery of novel therapeutic targets and the development of ultra-sensitive diagnostic assays, particularly targeting pathways like PAR and c-Abl. As a subsidiary of D&D Pharmatech/Neuraly, ValtedSeq is positioned to translate its foundational discoveries into clinical programs.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Modulo Bio | Discovery |
| PBI-01207 | Phoenix Biotechnology | Pre-clinical |
| Undisclosed Neurology Program(s) | Base4 | Preclinical |
| Platform Application for Neurodegenerative Diseases | ALTUCELL | Pre-clinical/Research |
| OGG1 Activator Program | Luciole Pharmaceuticals | Pre-clinical |
| Lysosome Biology Program | Talisman Therapeutics | Preclinical |
| Microglial Health Program | Talisman Therapeutics | Preclinical |
| HSF1 Activator Program | Sisu Pharma | Pre-clinical |
| Platform-derived candidates | VRG Therapeutics | Pre-clinical |
| Neurodegenerative Biomarkers R&D | Firalis | Development |
| Neurodegeneration Pipeline | Origenis | Preclinical |
| Enhanced Brain Delivery (EBD™) Platform | Acumen Pharmaceuticals | Preclinical |